Page 84 - Read Online

Page 12 of 15 Song et al. Hepatoma Res 2020;6:27 I http://dx.doi.org/10.20517/2394-5079.2020.05

37. Zhang R, Real CI, Liu C, Baba HA, Gerken G, et al. Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B
virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro. Int J Cancer
2017;141:354-63.
38. Luan F, Liu H, Gao L, Liu J, Sun Z, et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional
activation of hTERT. Gut 2009;58:1528-37.
39. Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, et al. High level of hepatitis B core-related antigen associated with increased risk of
hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 2019;157:1518-29.e3.
40. Liu W, Guo TF, Jing ZT, Yang Z, Liu L, et al. Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src
expression and activating the Src/PI3K/Akt pathway. FASEB J 2018;32:3033-46.
41. Liu D, Cui L, Wang Y, Yang G, He J, et al. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma
by interacting with NUMB and decreasing p53 activity. Hepatology 2016;64:390-404.
42. Xie Q, Fan F, Wei W, Liu Y, Xu Z, et al. Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein
in hepatocellular carcinoma cells. Sci Rep 2017;7:41089.
43. Du J, Liang X, Liu Y, Qu Z, Gao L, et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking
DR5 expression. Cell Death Differ 2009;16:219-29.
44. Liu W, Lin YT, Yan XL, Ding YL, Wu YL, et al. Hepatitis B virus core protein inhibits Fas-mediated apoptosis of hepatoma cells via
regulation of mFas/FasL and sFas expression. FASEB J 2015;29:1113-23.
45. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in
an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol
2018;92.
46. Duan M, Hao J, Cui S, Worthley DL, Zhang S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma
revealed by single-cell genome sequencing. Cell Res 2018;28:359-73.
47. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.
Nat Commun 2016;7:12992.
48. Yang X, Wu L, Lin J, Wang A, Wan X, et al. Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent
normal liver tissue. Int J Cancer 2017;140:1324-30.
49. Wong DK, Cheng SCY, Mak LL, To EW, Lo RC, et al. Among patients with undetectable hepatitis B surface antigen and
hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol
Hepatol 2020;18:449-56.
50. Yan H, Yang Y, Zhang L, Tang G, Wang Y, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early-
and late-onset hepatocellular carcinoma. Hepatology 2015;61:1821-31.
51. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic
chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256-64.
52. Li CL, Li CY, Lin YY, Ho MC, Chen DS, et al. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription
after hepatitis B virus integration or point mutation in promoter region. Hepatology 2019;69:498-512.
53. Yoo S, Wang W, Wang Q, Fiel MI, Lee E, et al. A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-
associated hepatocellular carcinoma with low- and high-degree liver fibrosis. BMC Med 2017;15:214.
54. Hama N, Totoki Y, Miura F, Tatsuno K, Saito-Adachi M, et al. Epigenetic landscape influences the liver cancer genome architecture.
Nat Commun 2018;9:1643.
55. Ren L, Zeng M, Tang Z, Li M, Wang X, et al. The antiresection activity of the X protein encoded by hepatitis virus B. Hepatology
2019;69:2546-61.
56. Musa J, Li J, Grunewald TG. Hepatitis B virus large surface protein is priming for hepatocellular carcinoma development via
induction of cytokinesis failure. J Pathol 2019;247:6-8.
57. Hsieh YH, Chang YY, Su IJ, Yen CJ, Liu YR, et al. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand
break repair and leads to genome instability in hepatocarcinogenesis. J Pathol 2015;236:337-47.
58. Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, et al. Recent insights into the multiple pathways driving non-alcoholic
steatohepatitis-derived hepatocellular carcinoma. Front Oncol 2019;9:762.
59. Li T, Weng J, Zhang Y, Liang K, Fu G, et al. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces
hepatocellular carcinoma. Cell Death Dis 2019;10:619.
60. Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic
reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391.
61. Kodama T, Yi J, Newberg JY, Tien JC, Wu H, et al. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular
carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci U S A 2018;115:e10417-26.
62. Ye J, Li TS, Xu G, Zhao YM, Zhang NP, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting
LATS2 kinase activity. Cancer Res 2017;77:5287-300.
63. Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, et al. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis
and liver cancer. J Clin Invest 2018;128:1010-25.
64. Inoue-Yamauchi A, Itagaki H, Oda H. Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. Carcinogenesis
2018;39:28-35.
65. Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, et al. A regulatory role of apoptosis antagonizing
transcription factor in the pathogenesis of nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatology 2019;69:1520-34.
66. He Y, Hwang S, Cai Y, Kim SJ, Xu M, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple
inflammatory and oncogenic genes in hepatocytes. Hepatology 2019;70:1150-67.